Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Epidemiology Forecast - 2030

DelveInsight’s "Gastroenteropancreatic Neuroendocrine Tumors —Epidemiology Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology of Gastroenteropancreatic Neuroendocrine Tumors in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Gastroenteropancreatic Neuroendocrine Tumors: Disease Understanding
Gastroenteropancreatic Neuroendocrine Tumors Overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. These cells release hormones that control various functions of the digestive system. The symptoms of GEP-NETs depend on where the tumor is growing in the gut, and whether it produces excess hormones. It is often that by the time of diagnosis, the tumors have spread to other organs such as the liver. GEP-NETs are debilitating as they often produce excess hormones that may cause severe symptoms, and they are life-threatening if they spread to other organs in the body.
The World Health Organization (WHO) 2010 and 2017 classification system categorizes GEP-NETs into three grades based on histological differentiation and cell proliferation index, guiding treatment decisions. Tumor grade is determined by the highest number of either Ki-67 protein or mitotic count, and it offers an important prognostic value for GEP-NETs. The median survival rates have been determined for all NETs across all locations by tumor grade. For individuals with grade 1 tumors, median survival is more than 16 years; for grade 2, about 8 years; and for grade 3, about 10 months. In 2017, WHO updated the staging classifications for pancreatic NETs (pNETs) to recognize well-differentiated grade 3 tumors. This will allow for more precisely targeted treatment options for grade 3 tumors. Poorly differentiated grade 3 pNETs may continue to be treated with standard systemic chemotherapy, whereas well- and moderately differentiated grade 3 pNETs have been shown to benefit from targeted therapies (everolimus or sunitinib). Well-differentiated pNETs may even benefit from surgery.
Surgery, the only curative treatment for GEP-NETs, is generally considered a first-line treatment for localized NETs. However, despite advances in diagnostics, GEP-NETs are often not identified for up to 5–7 years after clinical symptoms appear, as the symptoms are not specific. Approximately 21% of well-differentiated NETs, 30% of moderately differentiated NETs, and 50% of poorly differentiated or undifferentiated NETs are diagnosed in the metastatic stage. Thus, many patients with GEP-NETs are not candidates for surgery and require systemic therapy after diagnosis. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA approved: [octreotide acetate] Sandostatin and lanreotide [Somatuline Depot]. If patients progress on frontline treatment, there is, at present, a lack of evidence regarding the next-best agent to choose from. Traditionally, mTOR inhibitor—everolimus or sunitinib [Sutent] — was acknowledged second-line agent, but with the recent approval of PRRT [peptide receptor radionuclide therapy], the choice of second-line therapy is debatable.
In the refractory setting, patients are encouraged to participate in clinical trials. For third- and fourth-line settings, there are some data regarding capecitabine/temozolomide, as well, especially in pancreatic NETs, in which the combination chemotherapy is very active. All available therapies for GEP-NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely.
Clinicians admit that many aspects of GEP-NETs are still unknown, and substantial efforts must be made to understand the disease better while advancing treatment options. There is a particular need for Phase II and III clinical trials to gain insight into treatment for grade 3 tumors, which have received less attention in the past because of grade 3 tumor rarity and poor pathology.
Gastroenteropancreatic Neuroendocrine Tumors: Epidemiology
The Gastroenteropancreatic Neuroendocrine Tumors epidemiology division provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Gastroenteropancreatic neuroendocrine tumors epidemiology segmented as the Incidence cases of Gastroenteropancreatic Neuroendocrine Tumors, Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, Site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, and Symptoms-specific cases of Gastroenteropancreatic Neuroendocrine Tumors. The report includes the incident scenario of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country-wise Gastroenteropancreatic Neuroendocrine Tumors Epidemiology
The epidemiology segment also provides the Gastroenteropancreatic Neuroendocrine Tumors epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident population of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM countries was estimated to be 23,115 cases in 2020.
As per the estimates, the United States had the highest incident population of Gastroenteropancreatic Neuroendocrine Tumors in 2020. Among the EU5 countries, Germany had the highest incident population of Gastroenteropancreatic Neuroendocrine Tumors with 2,025 cases, followed by France in 2020. On the other hand, Spain had the lowest incident population of 1,161 cases in 2020.
Scope of the Report
• Gastroenteropancreatic Neuroendocrine Tumors report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Report and Model provide an overview of the risk factors and global trends of Gastroenteropancreatic Neuroendocrine Tumors in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Gastroenteropancreatic Neuroendocrine Tumors in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Gastroenteropancreatic Neuroendocrine Tumors.
• The report provides the segmentation of the Gastroenteropancreatic Neuroendocrine Tumors epidemiology by incident cases of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM.
• The report provides the segmentation of the Gastroenteropancreatic Neuroendocrine Tumors epidemiology by grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM.
• The report provides the segmentation of the Gastroenteropancreatic Neuroendocrine Tumors epidemiology by site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM.
• The report provides the segmentation of the Gastroenteropancreatic Neuroendocrine Tumors epidemiology by stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM.
• The report provides the Gastroenteropancreatic Neuroendocrine Tumors epidemiology segmentation by symptoms-specific Gastroenteropancreatic Neuroendocrine Tumors cases in the 7MM.

Report Highlights
• 10-year Forecast of Gastroenteropancreatic Neuroendocrine Tumors epidemiology
• 7MM Coverage
• Incident Cases of Gastroenteropancreatic Neuroendocrine Tumors
• Grade-specific Cases of Gastroenteropancreatic Neuroendocrine Tumors
• Site-specific Cases of Gastroenteropancreatic Neuroendocrine Tumors
• Stage-specific Cases of Gastroenteropancreatic Neuroendocrine Tumors
• Symptoms-specific Cases of Gastroenteropancreatic Neuroendocrine Tumors

KOL Views
We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What major factors will drive the change in the patient population in Gastroenteropancreatic Neuroendocrine Tumors during the forecast period (2018–2030)?
• What are the key findings pertaining to the Gastroenteropancreatic Neuroendocrine Tumors epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018–2030)?
• What would be the total number of patients with Gastroenteropancreatic Neuroendocrine Tumors across the 7MM during the forecast period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2018–2030)?
• What are the disease risk, burdens, and unmet needs of Gastroenteropancreatic Neuroendocrine Tumors?
• What are the currently available treatments for Gastroenteropancreatic Neuroendocrine Tumors?
Reasons to buy
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global Gastroenteropancreatic Neuroendocrine Tumors market.
• Quantify patient populations in the global Gastroenteropancreatic Neuroendocrine Tumors market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gastroenteropancreatic Neuroendocrine Tumors therapeutics in each market covered.
• Understand the magnitude of the Gastroenteropancreatic Neuroendocrine Tumors population by its incident cases.
• Understand the magnitude of the Gastroenteropancreatic Neuroendocrine Tumors population by its grade-specific cases.
• Understand the magnitude of the Gastroenteropancreatic Neuroendocrine Tumors population by its site-specific cases.
• Understand the magnitude of the Gastroenteropancreatic Neuroendocrine Tumors population by its stage-specific cases.
• Understand the magnitude of the Gastroenteropancreatic Neuroendocrine Tumors population by its symptoms-specific cases.
• The Gastroenteropancreatic Neuroendocrine Tumors epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030
A study by Jalbert et al. (2020) identified 682 patients with advanced GEP‐NETs, out of which 597 (87.0%) initiated ≥1 treatment over the follow‐up period. For this study, the author identified patients with a well‐differentiated, metastatic GEP‐NET evaluated at Dana‐Farber Cancer Institute between July 2003 and May 2015. As per the results, a total of 83.1% initiated a somatostatin analog (SSA) as their first‐line treatment, with 55% and 31% of patients continuing with second-and third‐line therapies. A total of 31.2% of patients with SSAs underwent dose escalation to above standard dose. The study demonstrates the common use of somatostatin analog as first‐line therapy for patients with advanced gastroenteropancreatic neuroendocrine tumors as well as the incorporation of multiple different treatment regimens in the treatment course of patients with this disease.